Abstracts tagged "Biologicals"

Abstract Number: 2021 • ACR Convergence 2023
Beliefs, Attitudes, and Preferences of Patients with Rheumatoid Arthritis (RA) and Concomitant Cancer with Respect to RA Therapy
Juan Ruiz¹, Sheneze Madramootoo², Maria A. Lopez-Olivo¹, Namrata Singh³ and Maria Suarez-Almazor⁴, ¹The University of Texas, MD Anderson Cancer Center, Houston, TX, ²The University of Texas MD Anderson Cancer Center, Houston, TX, ³University of Washington, Bellevue, WA, ⁴MD Anderson Cancer Center, Houston, TX
Background/Purpose: Treatment of rheumatoid arthritis (RA) in patients with cancer could potentially result in poor cancer outcomes because of immunosuppression. Adequate data for shared decision-making…
Abstract Number: 2224 • ACR Convergence 2023
Difficult to Treat Axial Spondyloarthritis. Predictors of Poor Outcomes
FERNANDO MONTERO¹, Laura Berbel Arcobé², Karen Carpio Astudillo¹, Jose Maria Bellón³ and Xavier Juanola Roura⁴, ¹Hospital General Universitario Gregorio Marañón, Madrid, Spain, ²H.U. Bellvitge, Barcelona, Spain, ³Gregorio Marañón Health Research Institute, Madrid, Spain, ⁴Hospital Universitari de Bellvitge, Barcelona, Spain
Background/Purpose: The term "Difficult-to-Treat" (D2T) defines those patients who remain active despite having undergone various treatments within the established recommendations. This concept is defined by…
Abstract Number: 2344 • ACR Convergence 2023
Telitacicept versus Belimumab for Patients with Active Systemic Lupus Erythematosus: A Retrospective, Multicenter, Real-world Observational Study
Zhu Chen¹, Huizhi Jin¹, Yujing Li¹, Guosheng Wang¹, Xiaomei Li², Zhijun Li³, Lin Niu⁴ and Haifeng Pan⁵, ¹University of Science and Technology of China, Hefei, China, ²University of Science and Technology of China, Department of Rheumatology and Immunology, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, Hefei, China, ³Bengbu Medical University, Bengbu, China, ⁴Fuyang People's Hospital, Fuyang, China, ⁵Anhui Medical University, Hefei, China
Background/Purpose: The past decade has witnessed the innovation of several biologics in the treatment of systemic lupus erythematosus (SLE), most of which target B cells,…
Abstract Number: 2546 • ACR Convergence 2023
Anti-infliximab Antibodies as a Marker of Drug Survival and Tapering in Ankylosing Spondylitis Patients: 12 Years Follow-up
CLARISSA PIMENTEL, ANA CRISTINA MEDEIROS-RIBEIRO, ANDREA SHIMABUCO, PERCIVAL SAMPAIO-BARROS, JULIO CESAR MORAES, CLAUDIA SCHAINBERG, CELIO GONÇALVES, ELAINE LEON, LEONARD KUPPA, Sandra Pasoto, NADIA AIKAWA, CLOVIS SILVA, Eloisa Bonfa and CARLA SAAD, University of São Paulo, São Paulo, Brazil
Background/Purpose: Tumor necrosis factor inhibitors (TNFi) therapies were one of the major advances in the treatment of Ankylosing Spondylitis (AS) patients. For infliximab, anti-drug antibodies…
Abstract Number: 0004 • ACR Convergence 2023
CD22 X CD79b Bispecific Ab Potently Inhibits B Cell Activation and Plasmablast Accumulation
Timothy Burwell¹, Jeffrey Hall¹, Suzanne Cole², Sarah Tursi¹, Isabelle Baribaud³, Kyle Bednar¹, Naresh Kumar¹, Julie Carman¹, Navin Rao² and Edith Janssen², ¹Janssen Research and Development, LLC, Spring House, PA, ²Janssen Research & Development, LLC, Spring House, PA, ³IGM Biosciences, Inc., Doylestown, PA
Background/Purpose: B cells contribute to the development and progression of autoimmune diseases through multiple mechanisms. Consequently, modulating B cell activation, B cell effector function, and…
Abstract Number: 0383 • ACR Convergence 2023
Identification of Contributing Factors to Difficult-to-Treat Rheumatoid Arthritis (D2T RA) in a Cohort of 972 Patients Using a Natural Language Processing (NLP) Approach
Hugo BERGIER¹, Thibaut Fabacher², Nathanaël Sedmak², Erik Sauleau² and Jacques-Eric Gottenberg³, ¹Hautepierre Hospital, Strasbourg, France, ²Hôpitaux Universitaires de Strasbourg, Strasbourg, France, ³Rheumatology Department, Strasbourg University Hospital, Strasbourg, France
Background/Purpose: Natural Language Processing (NLP), an interdisciplinary field combining artificial intelligence and language science, has gained significant interest in the medical domain for automated collection…
Abstract Number: 0520 • ACR Convergence 2023
How Do Early Disease Activity and Early Clinical Response Associate with Long-Term Outcomes with Ixekizumab in Radiographic Axial Spondyloarthritis?
Sofia Ramiro¹, Cedric Lukas², Louis Bessette³, Pendleton Wickersham⁴, Soyi Liu-Leage⁵, Tommaso Panni⁵, Rebecca Bolce⁵, Boris Janos⁵, Michael Nissen⁶ and James Cheng-Chung Wei⁷, ¹Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ²CHU Montpellier, Montpellier, France, ³Centre de l'Ostéoporose et de Rhumatologie de Québec, Quebec City, QC, Canada, ⁴Arthritis Associates PA, San Antonio, TX, ⁵Eli Lilly and Company, Indianapolis, IN, ⁶Geneva University Hospitals, Geneva, Switzerland, ⁷Chung Shan Medical University Hospital, Department of Rheumatology, Taichung, Taiwan
Background/Purpose: The ASAS-EULAR recommendations for the management of axial spondyloarthritis (axSpA) advise that a patient be assessed for biological disease-modifying anti-rheumatic drug (bDMARD) treatment response…
Abstract Number: 0604 • ACR Convergence 2023
Is Belimumab Dose Optimization Possible in Patients with Systemic Lupus Erythematosus?: Analysis of This Therapeutic Strategy in a Large Multicenter Cohort of Patients from Spanish Rheumatology Departments
Irene Altabas Gonzalez¹, Jose-Maria Pego-Reigosa², CORAL Mourino Rodriguez³, Norman Jiménez⁴, Andrea Hernández-Martín⁵, Judit Font⁶, Ivette Casafont-Sole⁷, Jose Andres Roman Ivorra⁸, Marta De la Rubia Navarro⁹, Maria Galindo¹⁰, TAREK CARLOS SALMAN MONTE¹¹, Javier Narvaez¹², Paola Vidal-Montal¹³, Maria J. García-Villanueva¹⁴, Sandra Garrote Corral¹⁴, María Ángeles Blázquez Cañamero¹⁵, carlos Marras Fernández-Cid¹⁶, María Piqueras García¹⁷, JULIA MARTINEZ BARRIO¹⁸, Marina Sánchez-Lucas¹⁹, Josefina Cortés Hernández²⁰, Eleonora Penzo²¹, Jaime Calvo Alén²², Juan Ramón de Dios Jiménez de Aberásturi²³, Belén Álvarez Rodríguez²⁴, Margarida Rocha²⁵, Eva Tomero Muriel²⁶, Raúl Menor-Almagro²⁷, Myriam Gandía Martínez²⁸, Jose A Gomez-Puerta²⁹, Beatriz Frade³⁰, Consuelo Ramos-Giráldez³¹, Carmen Trapero Pérez³², MARIA ELVIRA DIEZ ALVAREZ³³, Clara Moriano Morales³³, Alejandro Muñoz³⁴ and Iñigo Rúa-Figueroa³⁵, ¹Complejo Hospitalario Universitario de Vigo, IRIDIS (Investigation in Rheumatology and Immune-Mediated Diseases) Group, Galicia Sur Health Research Institute, Vigo, Spain, ²Rheumatology, Hospital do Meixoeiro, Vigo, Spain, ³Complejo Hospitalario Universitario de Vigo. IRIDIS (Investigation in Rheumatology and Immune-Mediated Diseases) Group, Galicia Sur Health Research Institute, Vigo, Spain, ⁴IIRIDIS (Investigation in Rheumatology and Immune-Mediated Diseases) Group, Galicia Sur Health Research Institute., Vigo, Spain, ⁵Hospital Universitario de Gran Canaria Dr. Negrin, Las Palmas de Gran Canaria, Spain, ⁶Hospital Universitario Germans Trias i Pujol, Badalona, Spain, ⁷Hospital Universitari Germans Trias i Pujol, Badalona, Spain, ⁸Hospital Universitari i Politècnic la Fe, Valencia, Spain, ⁹Hospital Universitario y Politécnico de la Fe, Valencia, Spain, ¹⁰Hospital Universitario 12 de Octubre, Madrid, Spain, ¹¹Hospital del Mar/Parc de Salut Mar-IMIM, Barcelona, Spain, ¹²Hospital Universitario de Bellvitge, Barcelona, Spain, ¹³Department of Rheumatology. Hospital Universitario de Bellvitge, Barcelona, Spain, ¹⁴Hospital Ramón y Cajal, Madrid, Spain, ¹⁵Rheumatology Department Hospital Ramon y Cajal, Madrid, Spain, ¹⁶Rheumatology, Hospital Virgen Arrixaca, Murcia, Spain, ¹⁷Hospital Virgen de la Arrixaca de Murcia, Murcia, Spain, ¹⁸Rheumatology, Gregorio Marañon University Hospital, Madrid, Spain, ¹⁹Hospital General Universitario Gregorio Marañón, Madrid, Spain, ²⁰Lupus Unit, Rheumatology Department, Vall d’Hebron Hospitals, Barcelona, Spain, ²¹Hospital Universitario Valle d´ Hebrón, Barcelona, Spain, ²²Hospital Universitario Araba, Vitoria, Spain, ²³Hospital Universitario Araba, Álava, Spain, ²⁴Hospital de Araba, Vitoria, Spain, ²⁵Osakidetza, Bilbo, Spain, ²⁶Rheumatology, Hospital La Princesa, Madrid, Spain, ²⁷Rheumatology, Hospital Jerez, Puerto De Santa María, Spain, ²⁸Hospital de Jerez, Jerez, Spain, ²⁹Department of Rheumatology, Hospital Clinic of Barcelona, Barcelona, Spain, ³⁰Hospital Clinic, Barcelona, Spain, ³¹Rheumatology Department Hospital Universitario Virgen de Valme, Sevilla, Spain, ³²Hospital Universitario Nuestra Señora de Valme, Sevilla, Spain, ³³Rheumatology, Hospital Universitario de León, León, Spain, ³⁴Hospital universitario Virgen del Rocío, El Viso de Alcor, Spain, ³⁵Rheumatology, Hospital de Gran Canaria Doctor Negrin, Las Palmas de Gran Canaria, Spain
Background/Purpose: Belimumab (BLM) is an IgG-1l anti-BAFF monoclonal antibody effective in patients with systemic lupus erythematosus (SLE), being used increasingly. However, there are no published…
Abstract Number: 1017 • ACR Convergence 2023
Cross Country Differences in b/tsDMARD Prescription Behavior: Associations Between Socioeconomics, Real World b/tsDMARD Use and Disease Outcomes
Isabell Nevins¹, Delphine COURVOISIER², Axel Finckh³, Ruth Fritsch-Stork⁴, Dan Nordstrom⁵, Ana Maria Rodrigues⁶, Stefan Dinescu⁷, Alvaro Garcia⁸, Mert Oztas⁹, Ziga Rotar¹⁰, Karen Salomon¹¹, Arvind Chopra¹², David Vega Morales¹³, Marieke De Buck¹⁴, Denis Choquette¹⁵, Richard Conway¹⁶, Florenzo Iannone¹⁷, CF Allaart¹⁸, Thomas Huizinga¹⁸, Kim Lauper¹⁹ and Sytske Anne Bergstra¹⁸, ¹Leiden University Medical Center, Amsterdam, Netherlands, ²Division of Rheumatology, Geneva University Hospitals, Geneva, Switzerland, ³HUG, Geneva, Switzerland, ⁴Medical Health center Mariahilf and Sigmund Freud Private University, Utrecht, Netherlands, ⁵Helsinki University Hospital, Helsinki, Finland, ⁶Sociedade Portuguesa de Reumatologia; Nova Medical School; Hospital dos Lusíadas, Lisbon, Portugal, ⁷University of Medicine and Pharmacy of Craiova, Craiova, Romania, ⁸University Hospital del Tajo, Madrid, Spain, ⁹Istanbul University-Cerrahpasa, Istanbul, Turkey, ¹⁰University Medical Centre Ljubljana, Ljubljana, Slovenia, ¹¹University of Massachusetts Medical School, Shrewsbury, MA, ¹²Center for Rheumatic Diseases, Pune, India, ¹³ROCHE, Ciudad de México, Mexico, ¹⁴Haaglanden Medisch Centrum, Den Haag, Netherlands, ¹⁵Centre hospitalier de l'Université de Montréal (CHUM), Université de Montréal, Montréal, QC, Canada, ¹⁶Trinity College Dublin, Dublin, Ireland, ¹⁷Rheumatology Unit, Department of Precision and Regenerative Medicine and Ionian Area, University of Bari "Aldo Moro", Bari, Italy, ¹⁸Leiden University Medical Center, Leiden, Netherlands, ¹⁹Geneva University Hospitals, Genève, Switzerland
Background/Purpose: The development of biologic and targeted synthetic (b/ts)DMARDs contributed to improved treatment outcomes in rheumatoid arthritis (RA). However, high medication costs may limit their…
Abstract Number: 1247 • ACR Convergence 2023
Pharmacokinetic, Pharmacodynamic, and Safety Profile of Subcutaneous Belimumab in Pediatric Patients with Systemic Lupus Erythematosus: Analysis of Data from a Multicenter, Open-Label Trial
Hermine Brunner¹, Diego Oscar Viola², Richard Dimelow³, Inmaculada Calvo Penadés⁴, Christel Wilkinson⁵, Juan Cruz Rizo Rodriguez⁶, Alina Boteanu⁷, Sylvia Kamphuis⁸, Kirsten Minden⁹, Gerd Horneff¹⁰, Jordi Anton¹¹, Masaaki Mori¹², Yuichi Yamasaki¹³, Jose Miyar Olaiz¹⁴, Rebecca Marino¹⁵, Andre van Maurik¹⁶, Mohamed Okily¹⁷, Emad Yanni¹⁸ and Paul WIlde¹⁹, ¹Cincinnati Children's Hospital Medical Center, Division of Rheumatology, Cincinnati, OH, ²CAICI Institute, Pediatric Rheumatology, Santa Fe, Argentina, ³GlaxoSmithKline, Clinical Pharmacology Modelling and Simulation, Stevenage, United Kingdom, ⁴Hospital Universitario y Politécnico La Fe, Pediatric Rheumatology Unit, València, Spain, ⁵GlaxoSmithKline, Clinical Statistics, Stevenage, United Kingdom, ⁶Centro de Alta Especialidad en Reumatologia e Investigacion del Potosi, San Luis Potosí, Mexico, ⁷Hospital Universitario Ramón y Cajal, Departamento de Reumatología, Madrid, Spain, ⁸Erasmus University Medical Center, Department of Pediatric Rheumatology, Rotterdam, Netherlands, ⁹Charité Universitätsmedizin Berlin, Department of Pediatric Respiratory Medicine, Immunology and Critical Care Medicine, Berlin, Germany, ¹⁰Asklepios Klinik Sankt Augustin GmbH, Bonn, Germany, ¹¹Hospital Sant Joan de Déu, Pediatric Rheumatology Department, Universitat de Barcelona, Barcelona, Spain, ¹²Tokyo Medical and Dental University Hospital, Department of Lifetime Clinical Immunology, Tokyo, Japan, ¹³Kagoshima University Hospital, Department of Pediatrics, Kagoshima, Japan, ¹⁴GlaxoSmithKline, Safety Evaluation and Risk Management, Brentford, United Kingdom, ¹⁵GlaxoSmithKline, Safety Evaluation and Risk Management, Durham, NC, ¹⁶GlaxoSmithKline, Clinical Pharmacology and Experimental Medicine, Brentford, United Kingdom, ¹⁷GlaxoSmithKline, Clinical Development, ImmunoInflammation, Brentford, United Kingdom, ¹⁸GlaxoSmithKline, Clinical Development, Rockville, MD, ¹⁹GlaxoSmithKline, Clinical Development, Brentford, United Kingdom
Background/Purpose: Belimumab (BEL) is an approved treatment for SLE, in addition to standard therapy. Intravenous (IV) BEL is approved in patients (pts) ≥5 years of…
Abstract Number: 1412 • ACR Convergence 2023
Improvements in Patient-Reported Outcomes Through 6 Months of Guselkumab Treatment in Patients with Active Psoriatic Arthritis: Real-World Data from the CorEvitas Psoriatic Arthritis/Spondyloarthritis (PsA/SpA) Registry
Philip J. Mease¹, Alexis R Ogdie², John Tesser³, Natalie shiff⁴, Iris Lin⁵, Soumya Chakravarty⁶, Mike Kelleman⁷, Rhiannon Dodge⁷, Robert McLean⁷, Aaron Broadwell⁸, Arthur Kavanaugh⁹ and Joseph F. Merola¹⁰, ¹Swedish Medical Center/Providence St. Joseph Health and University of Washington School of Medicine, Seattle, WA, ²University of Pennsylvania, Philadelphia, PA, ³Arizona Arthritis & Rheumatology Associates, Phoenix, AZ, ⁴Immunology, Janssen Scientific Affairs, LLC / Adjunct, Community Health and Epidemiology, University of Saskatchewan, Horsham, PA, ⁵Janssen, Horsham, PA, ⁶Immunology, Janssen Scientific Affairs, LLC / Division of Rheumatology, Drexel University College of Medicine, Villanova, PA, ⁷CorEvitas, LLC, Waltham, MA, ⁸Department of Rheumatology, Rheumatology and Osteoporosis Specialists, Shreveport, LA, ⁹Division of Rheumatology, Allergy, and Immunology, University of California San Diego, La Jolla, CA, ¹⁰Brigham and Women's Hospital and Harvard Medical School, Boston, MA
Background/Purpose: Guselkumab (GUS) has demonstrated significant efficacy across disease domains in controlled clinical trials of patients (pts) with active PsA.1,2 Recent CorEvitas PsA/SpA Registry analyses…
Abstract Number: 1582 • ACR Convergence 2023
Non-TNFi b/tsDMARDs vs. TNFi in Rheumatoid Arthritis-Interstitial Lung Disease: An Active-Comparator, New-User, Propensity Score Matched Study Using National Veterans Affairs Data
Bryant England¹, Joshua Baker², Michael George², Tate Johnson¹, Yangyuna Yang¹, Punyasha Roul¹, Harlan Sayles¹, Fang Yu¹, Jorge Rojas Jr³, Brian Sauer⁴, Grant Cannon⁵, Jeffrey R Curtis⁶ and Ted R Mikuls⁷, ¹University of Nebraska Medical Center, Omaha, NE, ²University of Pennsylvania, Philadelphia, PA, ³Puget Sound VA and University of Utah, Seattle, WA, ⁴Salt Lake City VA/University of Utah, Salt Lake City, UT, ⁵University of Utah and Salt Lake City VA, Salt Lake City, UT, ⁶Division of Clinical Immunology and Rheumatology, University of Alabama, Birmingham, AL, ⁷Division of Rheumatology and Immunology, University of Nebraska Medical Center, Omaha, NE
Background/Purpose: There is a paucity of data to guide biologic and JAKi DMARD selection in rheumatoid arthritis-interstitial lung disease (RA-ILD), with some reports of higher…
Abstract Number: 2052 • ACR Convergence 2023
Risk Factors for Hospitalization for SARS-CoV-2 in Pediatric Patients with Rheumatic Diseases: A Systematic Review and Meta-analysis
Qianzi Zhao¹, Beth Wallace², Lawrence Jung³ and Tova Ronis⁴, ¹Trinity Health Ann Arbor, Ann Arbor, MI, ²Michigan Medicine, VA Ann Arbor Healthcare System, Ann Arbor, MI, ³Jung Medical, Cedar Falls, IA, ⁴Children's National Hospital, Chevy Chase, MD
Background/Purpose: Among adults who develop SARS-CoV-2 infection, those with rheumatic diseases (RDs) have similar hospitalization rates compared to those without RDs. Similar comparisons are lacking…
Abstract Number: 2227 • ACR Convergence 2023
The Impact of Smoking Status on One Year Secukinumab Retention Rate in 1,684 Patients with PsA: Real-World Results from the EuroSpA Collaboration
Zohra Faizy Ahmadzay¹, Stylianos Georgiadis², Marion Pons², Merete Hetland², Bente Glintborg³, Jette Heberg², Sara Nysom Christiansen², Simon Horskjær Rasmussen², Anne Gitte Loft⁴, Isabel Castrejon⁵, Lucia Otero-Valera⁶, Jakub Zavada⁷, Karel Pavelka⁸, Heikki Relas⁹, Laura Kuusalo¹⁰, Burkhard Moeller¹¹, Michael Nissen¹², Ziga Rotar¹³, Katja Perdan Pirkmajer¹⁴, Daniela Santos Oliveira¹⁵, Ana Rita Cruz-Machado¹⁶, Brigitte Michelsen¹⁷, Eirik Kristianslund¹⁸, Bjorn Gudbjornsson¹⁹, Gerdur Maria Grondal²⁰, Karin Laas²¹, Pasoon Hellamand²², Ismail Sari²³, Daniela Di Giuseppe²⁴, Mikkel Østergaard²⁵ and Lykke Ørnbjerg², ¹Rigshospitalet Glostrup, University of Copenhagen, Glostrup, Denmark, ²Copenhagen Center for Arthritis Research, Rigshospitalet, Copenhagen, Denmark, ³Rigshospitalet Glostrup, University of Copenhagen, Virum, Denmark, ⁴Aarhus University, Horsens, Denmark, ⁵Hospital General Universitario Gregorio Marañón, Madrid, Spain, ⁶Spanish Society of Rheumatology, Madrid, Spain, ⁷Institute of Rheumatology; Charles University, Prague, Czech Republic, ⁸Institut of Rheumatology and Department of Rheumatology, First Faculty of Medicine, Charles University, Praha, Czech Republic, ⁹Helsinki University Hospital, Helsinki, Finland, ¹⁰Division of Internal Medicine, Centre for Rheumatology and Clinical Immunology, University of Turku and Turku University Hospital, Turku, Finland, ¹¹Inselspital - University Hospital Bern, Bern, Switzerland, ¹²Geneva University Hospitals, Geneva, Switzerland, ¹³University Medical Centre Ljubljana, Ljubljana, Slovenia, ¹⁴Department of Rheumatology, University Medical Centre LJubljana, Ljubljana, Slovenia, ¹⁵Department of Medicine, Faculty of Medicine, University of Porto, Rheumatology Department, Centro Hospitalar e Universitário de São João, Porto, Portugal, ¹⁶Rheumatology and Metabolic Bone Diseases Department, Hospital de Santa Maria, CHULN, Academic Medical Center and ERN-ReCONNET; Instituto de Medicina Molecular João Lobo Antunes, Faculdade de Medicina da Universidade de Lisboa; Reuma.pt Sociedade Portuuesa de Reumatologia, Lisbon, Portugal, ¹⁷Rigshospitalet Glostrup; Diakonhjemmet Hospital; Sørlandet Hospital, Copenhagen, Denmark, ¹⁸Diakonhjemmet Hospital, Oslo, Norway, ¹⁹Centre for Rheumatology Research, University Hospital, Reykjavik, Iceland, ²⁰Department for Rheumatology, Landspitali University Hospital, Reykjavik, Iceland, ²¹Department of Rheumatology, East-Tallinn Central Hospital, Tallinn, Estonia, ²²Amsterdam University Medical Centers, University of Amsterdam, Amsterdam, Netherlands, ²³Division of Rheumatology, Department of Internal Medicine, Dokuz Eylul University School of Medicine, Izmir, Turkey, ²⁴Karolinska Institutet, Stockholm, Sweden, ²⁵Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Centre for Head and Orthopaedics, Rigshospitalet; University of Copenhagen, Copenhagen, Denmark
Background/Purpose: Smoking has been associated with higher disease activity, poorer treatment response, and drug retention rate among psoriatic arthritis (PsA) patients treated with Tumor Necrosis…
Abstract Number: 2346 • ACR Convergence 2023
SLE Medication Usage and Organ Damage Among Adult SLE Patients with SLE Treated with Belimumab (BEL): Pooled Data from Three Open-Label Extension Studies over 11+ Years
Zahi Touma¹, Cristina Arriens², Christine Henning³, Angela Carroll³, Paula Curtis⁴, Roger A. Levy⁵ and William Stohl⁶, ¹University of Toronto, Toronto, ON, Canada, ²Oklahoma Medical Research Foundation and University of Oklahoma Health Sciences Center, Department of Arthritis & Clinical Immunology, Oklahoma City, OK, ³GlaxoSmithKline, US Medical Affairs, Durham, NC, ⁴GlaxoSmithKline, R&D Biostatistics, Brentford, United Kingdom, ⁵GlaxoSmithKline, Global Medical Affairs, Collegeville, PA, ⁶University of Southern California Keck School of Medicine, Division of Rheumatology, Los Angeles, CA
Background/Purpose: A key treatment goal for patients (pts) with SLE is to reduce use of CS, due to their association with organ damage.1 BEL is…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].